Logic-Gated Biology, Novel Antigens, and the Next Frontier of Precision Immune Engagement

Session details:

This session explores how logic-gated therapeutics, dual-antigen recognition, conditional binding, and novel antigen discovery platforms may enable safer and more precise tumor targeting.

• Can AND-gate targeting solve on-target/off-tumor toxicity?
• Which modalities are best suited for logic-gated approaches: TCEs, ADCs, or cell therapies?
• Are novel antigens more valuable than better antibody engineering?
• What does clinical validation need to look like for these platforms?